Global Monoclonal Antibodies (mAbs) Market – North America is expected to account for higher market share of more than 75% driven by presence of well-established healthcare infrastructure – Global Market Analysis 2013 – 2017 and Forecast 2018 – 2024

Global Monoclonal Antibodies (mAbs) Market – North America is expected to account for higher market share of more than 75% driven by presence of well-established healthcare infrastructure – Global Market Analysis 2013 – 2017 and Forecast 2018 – 2024

Market Scenario

Global Monoclonal Antibodies (mAbs) Market is expected to grow at a CAGR of 7% to reach US$ 11.78 billion in 2024. The growth is coupled with Increasing R&D activities in genomics coupled with the advent of technologically advanced genetic platforms, such as next-generation sequencing, pose as the major drivers. In addition, the cost-effective nature of the technology is supporting its incorporation in performing research studies to develop mAbs. These are widely accepted biologics and are expected to present a billion-dollar opportunity to pharmaceutical manufacturers over the forecast period. Growing awareness levels amongst patients and physicians pertaining to the applications of mAb therapy are contributing to further growth. Moreover, approval of blockbuster mAbs for a variety of indications is expected to boost the usage rates over the forecast period. For instance, significant revenue generating drugs such as Avastin, Herceptin, Remicade, and Rituxan with FDA approval for an array of conditions (cancer, rheumatoid arthritis, Crohn's disease, ulcerative colitis etc.) further boost the patient base. Global Monoclonal Antibodies (mAbs) Market is predicted to grow at a lucrative CAGR due to the presence of a strong product pipeline. North America had the highest market share in 2017. The Global Monoclonal Antibodies (mAbs) Market is driven by the presence of well-established healthcare infrastructure. Moreover, increasing government funding for cancer research and technology development is anticipated to boost the development of therapeutic proteins over the forecast period. Government support in infection control & management, rising incidence of lifestyle-associated diseases, and the escalating population number are other crucial factors aiding the growth of this sector. Asia Pacific region is expected to exhibit considerable growth owing to rising disposable income, the presence of huge untapped potential, increased expenditure in research & development, and growing patient awareness pertaining to the therapeutic use of mAbs. In vivo technology is cost effective as compared to in vitro production techniques and is preferred for the high concentration of mAbs obtained through this method. However, the availability of several in vitro methods is expected to hamper the adoption of in vivo production techniques in the coming years. The associated benefits of employing in vitro methods for antibody generation, including time efficiency, economic viability, and large-scale production, are anticipated to fuel the segment growth over the forecast period. Global Monoclonal Antibodies (mAbs) Market Global Monoclonal Antibodies (mAbs) MarketSegmentation: • Global Monoclonal Antibodies (mAbs) Market, By Source Type: o Murine o Chimeric o Humanized o Human •Global Monoclonal Antibodies (mAbs) Market,  By Production Type: o In Vivo o In Vitro •Global Monoclonal Antibodies (mAbs) Market,  By Indications: o Cancer o Autoimmune Diseases o Inflammatory Diseases o Infectious Diseases o Microbial Diseases o Others • Global Monoclonal Antibodies (mAbs) Market, By End User: o Hospitals o Research Institutes o Others The above data will be provided for following regions/countries from 2013-2024 (USD Million) • North America o U.S. o Canada • Europe o Germany o UK o France o Spain o Italy • Asia Pacific o China o India o Japan o Australia • Latin America o Argentina o Brazil o Mexico • Middle East and Africa o South Africa o Saudi Arabia What information is covered in the Report? • Actual market numbers from 2013-2017, estimates and forecasts from 2018 to 2024 • Detailed market segmentation and market share analysis of each segment • Impact analysis of various drivers and trends • Market segmentation and landscape • Competitive landscape, 2017 Global Vascular Patches Devices Market

Table of Contents

Global Monoclonal Antibodies (mAbs) Market

Chapter 1 Research Methodology 1.1. Research Methodology 1.2. Market definition 1.3. Assumptions and Acronyms Used 1.4. Data Sources 1.4.1. Secondary 1.4.1.1. Paid 1.4.1.2. Unpaid 1.4.2. Primary Chapter 2 Executive Summary 2.1. Global Monoclonal Antibodies Market overview 2.1.1. By Source Type 2.1.2. By Production Type 2.1.3. By Indication 2.1.4. By End User Chapter 3 Global Monoclonal Antibodies Market Industry Insights 3.1. Market segmentation and scope of study 3.2. Market Drivers and their impact analysis 3.2.1. Market Drivers 3.2.1.1. Increasing incidences of cancer 3.2.1.2. Rapid technological advancements 3.2.2. Market Restrains 3.2.2.1. Unawareness for the diagnosis of chronic diseases 3.3. Market share analysis 3.3.1. By Source Type 3.3.2. By Production Type 3.3.3. By Indication 3.3.4. By End User 3.4. Competitive analysis 3.4.1. Key strategic initiatives 3.4.2. Regional presence 3.4.3. Product overview 3.5. Porter’s analysis 3.6. PESTEL analysis Chapter 4 Monoclonal Antibodies Market, By Production Type 4.1. Key segment trends 4.2. In Vivo 4.2.1. Market size, by region, 2013 - 2024 4.3. In Vitro 4.3.1. Market size, by region, 2013 – 2024 4.3.2. Key Trends in Global Monoclonal Antibodies Market Chapter 5 Monoclonal Antibodies Market, By Source Type 5.1. Key segment trends 5.2. Murine 5.2.1. Market size, by region, 2013 - 2024 5.3. Chimeric 5.3.1. Market size, by region, 2013 – 2024 5.4. Humanized 5.4.1. Market size, by region, 2013 – 2024 5.5. Human 5.5.1. Market size, by region, 2013 - 2024 Chapter 6 Monoclonal Antibodies Market, By Indications 6.1. Key segment trends 6.2. Cancer 6.2.1. Market size, by region, 2013 - 2024 6.3. Autoimmune Diseases 6.3.1. Market size, by region, 2013 – 2024 6.4. Inflammatory Diseases 6.4.1. Market size, by region, 2013 – 2024 6.5. Infectious Diseases 6.5.1. Market size, by region, 2013 – 2024 6.6. Microbial Diseases 6.6.1. Market size, by region, 2013 – 2024 6.1. Others 6.1.1. Market size, by region, 2013 – 2024 Chapter 7 Monoclonal Antibodies Market, By End-User 7.1. Key segment trends 7.2. Hospitals 7.2.1. Market size, by region, 2013 - 2024 7.3. Research Institutes 7.3.1. Market size, by region, 2013 – 2024 7.4. Others 7.4.1. Market size, by region, 2013 – 2024 Chapter 8 Monoclonal Antibodies Market, By Region 8.1. Key regional trends 8.2. North America 8.2.1. Market size, by country, 2013 – 2024 8.2.2. Market size, by production type, 2013 – 2024 8.2.3. Market size, by source type, 2013 – 2024 8.2.4. Market size, by indications, 2013 – 2024 8.2.5. Market size, by end-user, 2013 – 2024 8.2.6. U.S. 8.2.6.1. Market size, by production type, 2013 – 2024 8.2.6.2. Market size, by source type, 2013 – 2024 8.2.6.3. Market size, by indications, 2013 – 2024 8.2.6.4. Market size, by end-user, 2013 – 2024 8.2.7. Canada 8.2.7.1. Market size, by production type, 2013 – 2024 8.2.7.2. Market size, by source type, 2013 – 2024 8.2.7.3. Market size, by indications, 2013 – 2024 8.2.7.4. Market size, by end-user, 2013 – 2024 8.3. Europe 8.3.1. Market size, by country, 2013 – 2024 8.3.2. Market size, by production type, 2013 – 2024 8.3.3. Market size, by source type, 2013 – 2024 8.3.4. Market size, by indications, 2013 – 2024 8.3.5. Market size, by end-user, 2013 – 2024 8.3.6. Germany 8.3.6.1. Market size, by production type, 2013 – 2024 8.3.6.2. Market size, by source type, 2013 – 2024 8.3.6.3. Market size, by indications, 2013 – 2024 8.3.6.4. Market size, by end-user, 2013 – 2024 8.3.7. UK 8.3.7.1. Market size, by production type, 2013 – 2024 8.3.7.2. Market size, by source type, 2013 – 2024 8.3.7.3. Market size, by indications, 2013 – 2024 8.3.7.4. Market size, by end-user, 2013 – 2024 8.3.8. France 8.3.8.1. Market size, by production type, 2013 – 2024 8.3.8.2. Market size, by source type, 2013 – 2024 8.3.8.3. Market size, by indications, 2013 – 2024 8.3.8.4. Market size, by end-user, 2013 – 2024 8.3.9. Spain 8.3.9.1. Market size, by production type, 2013 – 2024 8.3.9.2. Market size, by source type, 2013 – 2024 8.3.9.3. Market size, by indications, 2013 – 2024 8.3.9.4. Market size, by end-user, 2013 – 2024 8.3.10. Italy 8.3.10.1. Market size, by production type, 2013 – 2024 8.3.10.2. Market size, by source type, 2013 – 2024 8.3.10.3. Market size, by indications, 2013 – 2024 8.3.10.4. Market size, by end-user, 2013 – 2024 8.4. Asia Pacific 8.4.1. Market size, by country, 2013 – 2024 8.4.2. Market size, by production type, 2013 – 2024 8.4.3. Market size, by source type, 2013 – 2024 8.4.4. Market size, by indications, 2013 – 2024 8.4.5. Market size, by end-user, 2013 – 2024 8.4.6. India 8.4.6.1. Market size, by production type, 2013 – 2024 8.4.6.2. Market size, by source type, 2013 – 2024 8.4.6.3. Market size, by indications, 2013 – 2024 8.4.6.4. Market size, by end-user, 2013 – 2024 8.4.7. China 8.4.7.1. Market size, by production type, 2013 – 2024 8.4.7.2. Market size, by source type, 2013 – 2024 8.4.7.3. Market size, by indications, 2013 – 2024 8.4.7.4. Market size, by end-user, 2013 – 2024 8.4.8. Japan 8.4.8.1. Market size, by production type, 2013 – 2024 8.4.8.2. Market size, by source type, 2013 – 2024 8.4.8.3. Market size, by indications, 2013 – 2024 8.4.8.4. Market size, by end-user, 2013 – 2024 8.4.9. Australia 8.4.9.1. Market size, by production type, 2013 – 2024 8.4.9.2. Market size, by source type, 2013 – 2024 8.4.9.3. Market size, by indications, 2013 – 2024 8.4.9.4. Market size, by end-user, 2013 – 2024 8.5. Latin America 8.5.1. Market size, by country, 2013 – 2024 8.5.2. Market size, by production type, 2013 – 2024 8.5.3. Market size, by source type, 2013 – 2024 8.5.4. Market size, by indications, 2013 – 2024 8.5.5. Market size, by end-user, 2013 – 2024 8.5.6. Argentina 8.5.6.1. Market size, by production type, 2013 – 2024 8.5.6.2. Market size, by source type, 2013 – 2024 8.5.6.3. Market size, by indications, 2013 – 2024 8.5.6.4. Market size, by end-user, 2013 – 2024 8.5.7. Brazil 8.5.7.1. Market size, by production type, 2013 – 2024 8.5.7.2. Market size, by source type, 2013 – 2024 8.5.7.3. Market size, by indications, 2013 – 2024 8.5.7.4. Market size, by end-user, 2013 – 2024 8.5.8. Mexico 8.5.8.1. Market size, by production type, 2013 – 2024 8.5.8.2. Market size, by source type, 2013 – 2024 8.5.8.3. Market size, by indications, 2013 – 2024 8.5.8.4. Market size, by end-user, 2013 – 2024 8.6. Middle East and Africa 8.6.1. Market size, by country, 2013 – 2024 8.6.2. Market size, by production type, 2013 – 2024 8.6.3. Market size, by source type, 2013 – 2024 8.6.4. Market size, by indications, 2013 – 2024 8.6.5. Market size, by end-user, 2013 – 2024 8.6.6. South Africa 8.6.6.1. Market size, by production type, 2013 – 2024 8.6.6.2. Market size, by source type, 2013 – 2024 8.6.6.3. Market size, by indications, 2013 – 2024 8.6.6.4. Market size, by end-user, 2013 – 2024 8.6.7. Saudi Arabia 8.6.7.1. Market size, by production type, 2013 – 2024 8.6.7.2. Market size, by source type, 2013 – 2024 8.6.7.3. Market size, by indications, 2013 – 2024 8.6.7.4. Market size, by end-user, 2013 – 2024 Chapter 9 Consolidations 9.1. Mergers and Acquisitions 9.2. Partnership, Joint Ventures and Strategic Alliances/Sales Agreements 9.3. Patent Analysis 9.4. Key players 9.4.1. Novartis AG 9.4.1.1. Company overview 9.4.1.2. Key financials 9.4.1.3. Product landscape 9.4.1.4. Strategic initiatives 9.4.1.5. SWOT analysis 9.4.2. Pfizer, Inc 9.4.2.1. Company overview 9.4.2.2. Key financials 9.4.2.3. Product landscape 9.4.2.4. Strategic initiatives 9.4.2.5. SWOT analysis 9.4.3. GlaxoSmithKline plc. 9.4.3.1. Company overview 9.4.3.2. Key financials 9.4.3.3. Product landscape 9.4.3.4. Strategic initiatives 9.4.3.5. SWOT analysis 9.4.4. Amgen, Inc. 9.4.4.1. Company overview 9.4.4.2. Key financials 9.4.4.3. Product landscape 9.4.4.4. Strategic initiatives 9.4.4.5. SWOT analysis 9.4.5. Merck & Co., Inc 9.4.5.1. Company overview 9.4.5.2. Key financials 9.4.5.3. Product landscape 9.4.5.4. Strategic initiatives 9.4.5.5. SWOT analysis 9.4.6. Daiichi Sankyo Company, Ltd. 9.4.6.1. Company overview 9.4.6.2. Key financials 9.4.6.3. Product landscape 9.4.6.4. Strategic initiatives 9.4.6.5. SWOT analysis 9.4.7. Abbott, AstraZeneca 9.4.7.1. Company overview 9.4.7.2. Key financials 9.4.7.3. Product landscape 9.4.7.4. Strategic initiatives 9.4.7.5. SWOT analysis 9.4.8. Olympus Corporation 9.4.8.1. Company overview 9.4.8.2. Key financials 9.4.8.3. Product landscape 9.4.8.4. Strategic initiatives 9.4.8.5. SWOT analysis 9.4.9. Boston Scientific Corporation 9.4.9.1. Company overview 9.4.9.2. Key financials 9.4.9.3. Product landscape 9.4.9.4. Strategic initiatives 9.4.9.5. SWOT analysis 9.4.10. FUJIFILM Holdings Corporation 9.4.10.1. Company overview 9.4.10.2. Key financials 9.4.10.3. Product landscape 9.4.10.4. Strategic initiatives 9.4.10.5. SWOT analysis 9.4.11. INRAD, Inc. 9.4.11.1. Company overview 9.4.11.2. Key financials 9.4.11.3. Product landscape 9.4.11.4. Strategic initiatives 9.4.11.5. SWOT analysis 9.4.12. Medtronic plc 9.4.12.1. Company overview 9.4.12.2. Key financials 9.4.12.3. Product landscape 9.4.12.4. Strategic initiatives 9.4.12.5. SWOT analysis 9.4.13. Leica Biosystems 9.4.13.1. Company overview 9.4.13.2. Key financials 9.4.13.3. Product landscape 9.4.13.4. Strategic initiatives 9.4.13.5. SWOT analysis 9.4.14. Hologic, Inc. 9.4.14.1. Company overview 9.4.14.2. Key financials 9.4.14.3. Product landscape 9.4.14.4. Strategic initiatives 9.4.14.5. SWOT analysis 9.4.15. Ethicon EndoSurgery Inc. 9.4.15.1. Company overview 9.4.15.2. Key financials 9.4.15.3. Product landscape 9.4.15.4. Strategic initiatives 9.4.15.5. SWOT analysis 9.4.16. Veran Medical Technologies 9.4.16.1. Company overview 9.4.16.2. Key financials 9.4.16.3. Product landscape 9.4.16.4. Strategic initiatives 9.4.16.5. SWOT analysis 9.4.17. Boston Scientific Corporation 9.4.17.1. Company overview 9.4.17.2. Key financials 9.4.17.3. Product landscape 9.4.17.4. Strategic initiatives 9.4.17.5. SWOT analysis 9.4.18. MDxHealth 9.4.18.1. Company overview 9.4.18.2. Key financials 9.4.18.3. Product landscape 9.4.18.4. Strategic initiatives 9.4.18.5. SWOT analysis 9.4.19. Mauna Kea Technologies 9.4.19.1. Company overview 9.4.19.2. Key financials 9.4.19.3. Product landscape 9.4.19.4. Strategic initiatives 9.4.19.5. SWOT analysis 9.4.20. Argon Medical Devices, Inc 9.4.20.1. Company overview 9.4.20.2. Key financials 9.4.20.3. Product landscape 9.4.20.4. Strategic initiatives 9.4.20.5. SWOT analysis 9.4.21. Intact Medical Corp. 9.4.21.1. Company overview 9.4.21.2. Key financials 9.4.21.3. Product landscape 9.4.21.4. Strategic initiatives 9.4.21.5. SWOT analysis 9.4.22. Carefusion Corporation 9.4.22.1. Company overview 9.4.22.2. Key financials 9.4.22.3. Product landscape 9.4.22.4. Strategic initiatives 9.4.22.5. SWOT analysis 9.4.23. Devicor Medical Products, Inc. 9.4.23.1. Company overview 9.4.23.2. Key financials 9.4.23.3. Product landscape 9.4.23.4. Strategic initiatives 9.4.23.5. SWOT analysis 9.4.24. DTR Medical 9.4.24.1. Company overview 9.4.24.2. Key financials 9.4.24.3. Product landscape 9.4.24.4. Strategic initiatives 9.4.24.5. SWOT analysis 9.4.25. Cardinal Health Inc. 9.4.25.1. Company overview 9.4.25.2. Key financials 9.4.25.3. Product landscape 9.4.25.4. Strategic initiatives 9.4.25.5. SWOT analysis

Inquiry Before Buying

Request Sample

About This Report

Report ID10977
Category Healthcare
Publisher Name
No of Pages
Total Views
Published Date
Contact Us
Call Now